ROCK inhibitors synergize with the BCL2 inhibitor venetoclax for treatment of AML

被引：0
|
作者：
Golla, Upendarrao
Patel, Satyam
Tukaramrao, Diwakar B.
Hengst, Jeremy
Restrepo, Juliana
Amin, Shantu
Desai, Dhimant
Dovat, Sinisa
Claxton, David
Sharma, Arati
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2677
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2677
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Salinomycin Nanoparticles Induce Ferroptosis and Synergize with the BCL-2 Inhibitor Venetoclax to Promote AML Cell Death
    Liu, Suiyang
    Ni, Wei
    Zhu, Fen
    Chowdhury, Basudev
    Galinsky, Ilene A.
    Davids, Matthew S.
    Weisberg, Ellen L.
    Kharbanda, Surender
    Stone, Richard M.
    BLOOD, 2024, 144 : 5820 - 5821
  • [2] THE BCL2 INHIBITOR VENETOCLAX IS ACTIVE IN NON-HODGKIN LYMPHOMA
    不详
    CANCER DISCOVERY, 2017, 7 (03) : 244 - 244
  • [3] Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
    Anderson, Mary Ann
    Tam, Constantine
    Lew, Thomas E.
    Juneja, Surender
    Juneja, Manu
    Westerman, David
    Wall, Meaghan
    Lade, Stephen
    Gorelik, Alexandra
    Huang, David C. S.
    Seymour, John F.
    Roberts, Andrew W.
    BLOOD, 2017, 129 (25) : 3362 - 3370
  • [4] BCL2 Inhibitors Target Diagnosed and Relapsed/Refractory AML
    Kontro, M.
    Majumder, M. M.
    Pemovska, T.
    Eldfors, S.
    Parsons, A.
    Kallioniemi, O.
    Wennerberg, K.
    Heckman, C. A.
    Porkka, K.
    ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 78 - 79
  • [5] BCL2 Inhibitors Target Diagnosed and Relapsed/Refractory AML
    Kontro, M.
    Majumder, M. M.
    Pemovska, T.
    Eldfors, S.
    Parsons, A.
    Kallioniemi, O.
    Wennerberg, K.
    Heckman, C. A.
    Porkka, K.
    ANNALS OF HEMATOLOGY, 2015, 94 : S78 - S79
  • [6] BCL2/MDM2 Inhibitor Combo Effective in AML
    Caruso, Catherine
    CANCER DISCOVERY, 2019, 9 (02) : 156 - 156
  • [7] BCL-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity in AML
    Brandwein, Joseph M.
    Basonbul, Asmaa
    BLOOD, 2019, 134
  • [8] JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML
    Karjalainen, Riikka
    Pemovska, Tea
    Popa, Mihaela
    Liu, Minxia
    Javarappa, Komal K.
    Majumder, Muntasir M.
    Yadav, Bhagwan
    Tamborero, David
    Tang, Jing
    Bychkov, Dmitrii
    Kontro, Mika
    Parsons, Alun
    Suvela, Minna
    Safont, Mireia Mayoral
    Porkka, Kimmo
    Aittokallio, Tero
    Kallioniemi, Olli
    McCormack, Emmet
    Gjertsen, Bjorn T.
    Wennerberg, Krister
    Knowles, Jonathan
    Heckman, Caroline A.
    BLOOD, 2017, 130 (06) : 789 - 802
  • [9] Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS
    Borthakur, Gautam M.
    Kadia, Tapan M.
    Al Azzawi, Hind
    Zheleva, Daniella
    Blake, David
    Chiao, Judy H.
    BLOOD, 2019, 134
  • [10] Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
    XiaoYan Yue
    Qingxiao Chen
    JingSong He
    Cancer Cell International, 20
12345